Ravulizumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | complement C5 |
Clinical data | |
Synonyms | ALXN1210 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6430H9888N1696O2028S48 |
Molar mass | 144.9 g/mol |
Ravulizumab (ALXN1210) (INN[1]) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemaglobinuria and atypical hemolytic uremic syndrome.
This drug was developed by Alexion Pharmaceuticals, Inc.[2]
It is currently at Phase III trials.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.